Cannabis Law Report

MAY 10, 2022

First comprehensive study reveals why Australians take medicinal cannabis. First academic study of national medicinal cannabis data. The first in-depth study of Australia’s medicinal cannabis program, which began in 2016, shows the drug is being increasingly prescribed for various conditions. 11 May 2022.

Medicine 52

Medicine Clinical Trials Sleep Data 52

TheAnswerPage

JANUARY 11, 2022

Are you able to answer your patients’ medical marijuana questions? Also, a recent systematic review of healthcare professionals’ “cannabis knowledge” reported “there was a unanimous lack of self-perceived knowledge surrounding all aspects of medicinal cannabis” (2). million medical marijuana patients nationwide.

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

SEPTEMBER 10, 2021

This exciting partnership between these innovative startups aims to advance patient access to psychedelic treatments in Europe, and improve the quality of the psychedelic medicines produced in Europe. We look forward to working closely with the Clerkenwell Health team to advance our psychedelic drug programs through clinical trials.”.

Research and Development 104

Research and Development Clinical Trials Therapy Environment 104

Cannabis Law Report

FEBRUARY 24, 2022

Subsection 56(1) of the CDSA will exempt medical providers from enforcement of the CDSA when providing psilocybin and MDMA treatment to patients suffering serious or terminal health conditions. Timeline of Medicinal Legalization in Canada. 01.015 of the FDR before providing the new drug to a patient. Pursuant to subsection C.08.010(1)

Therapy 52

Therapy Access Clinical Trials Treatment 52

Cannabis Law Report

AUGUST 7, 2021

MAPS PBC catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics. The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times.

Clinical Trials 105

Clinical Trials Research and Development Compliance Compliance 105

MMJ Recs

DECEMBER 17, 2023

The Texas Compassionate Use Program (TCUP) represents the Lone Star State’s cautious foray into the realm of medical marijuana. Enacted in 2015, the program was designed to provide a narrow avenue for patients suffering from qualifying conditions to access low-THC cannabis under the supervision of qualified healthcare professionals.

Law 52

Law Dispensary Clinical Trials Programs 52

Cannabis Law Report

AUGUST 10, 2022

According to CAMH’s lead investigator, clinical trials suggest that psilocybin, combined with psychotherapy, can produce “ sustained antidepressant effects” in individuals living with severe depression. Optimi Health Corp.

Clinical Trials 52

Clinical Trials Research and Development Therapy Microdosing 52

Cannabis Law Report

AUGUST 14, 2021

The deal signed in March had sought to progress an over-the-counter medicine with the TGA using Emyria’s EMD-003 program and Cann’s Gelpell technology. Cann Group (CAN) and Emyria (EMD) mutually agree to drop a deal for the proposed registration of a Schedule 3 cannabidiol (CBD) product. Shares in Cann Group were up 3.33

CBD 105

CBD Clinical Trials Programs Medicine 105

Cannabis Law Report

JUNE 11, 2021

NEW YORK, June 9, 2021 /PRNewswire/ — Mind Medicine (MindMed) Inc. NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading clinical-stage pharmaceutical company and pioneer in the field of psychedelic inspired medicines, announces that J.R. Here’s the press release.

Clinical Trials 95

Clinical Trials Research and Development Pharmaceutical Medicine 95

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). Secondary endpoint of 50% responder rate at 30.4%, consistent with the Marigold Phase 3 CDKL5 deficiency disorder trial results. reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

MMJ Recs

APRIL 1, 2024

Furthermore, ongoing clinical trials are investigating CBD’s efficacy in treating conditions such as multiple sclerosis, Parkinson’s disease, and substance abuse disorders. Exploring CBD for Medical Use As interest in CBD grows, researchers are continuously exploring its potential applications in the medical field.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

DECEMBER 9, 2021

The Company believes it has produced a sufficient supply of cGMP DMT to complete its planned Phase 1 and Phase 2 clinical trials. as medical consultants to the Company’s DMT stroke clinical research program. in the latter part of 2022, after the Phase 1 trial has been completed. Dr. Anthony Rudd.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Veriheal

APRIL 11, 2022

The final goal is to introduce medicinal cannabis products to the pharmaceutical drug market. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website. territories. This means that U.S.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

SpeedWeed

AUGUST 11, 2021

“This grant enables more rigorous study, overseen by the FDA, which may lead to cannabis flower becoming prescribable medicine someday. The grant comes from Michigan’s 2021 Veteran Marijuana Research Grant Program , and is funded by the state’s recreational cannabis taxes. MAPS Makes History. The study was funded with $2.2

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical DEA 52

Cannabis Law Report

JUNE 23, 2021

. “Listing on the NEO is an important milestone for Awakn to continue to build on our dual strategic focus of developing psychedelic drugs, therapies, and enabling technologies to treat Addiction, and delivering psychedelic treatments for Addiction in our clinics,” said Awakn CEO, Anthony Tennyson. David Nutt), starts in Q4 2021.

Clinical Trials 110

Clinical Trials Therapy Research and Development Treatment 110

SpeedWeed

SEPTEMBER 17, 2021

Data collected from MAPS-sponsored Phase 3 clinical trials suggests that MDMA-assisted therapy appears promising in the treatment of TBI. Wesana outlined five key goals: Gain expertise and information to design psychedelic-assisted therapy programs for TBI and improve the Wesana timeline and path to market for its treatments.

Clinical Trials 53

Clinical Trials Research and Development Therapy Treatment 53

Cannabis Law Report

MAY 29, 2022

Businesses have been recently receiving approval from Health Canada to farm psychedelic mushrooms, make psilocybin and sell the compound to drug-makers, or to doctors to give to patients. This is a natural medicine. They’re creating medicine synthetically, and giving it to people to do exactly what this can do.

Research and Development 52

Research and Development Clinical Trials Medicine Access 52

The Cannigma

OCTOBER 14, 2022

San Marino medical marijuana program. Established in 2016 by a citizen’s initiative, patients can purchase cannabis-based medicines like Sativex to treat a number of approved conditions including multiple sclerosis, spine injuries, and neuropathic pain. The program does not include cannabis flower or home grow.

Law 56

Law Clinical Trials Research and Development Recreational 56

Cannabis Law Report

NOVEMBER 19, 2021

MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD. We are committed to continuing to lead the field of psychedelic medicine with integrity and ethics at the core. Why work for MAPS Public Benefit Corporation (MAPS PBC)?

Clinical Trials 52

Clinical Trials Research and Development Therapy Compliance 52

Veriheal

AUGUST 31, 2020

These students showed knowledge and passion for the future of cannabis and posed revolutionary ideas rooted in their training across business, agriculture, biochemistry, public health, pharmacology, medicine, and liberal arts. . Essay: “Integrating Research and Medicine: Cannabis Related Treatment for Neurodegenerative Diseases”.

Research and Development 117

Research and Development Education Agriculture Patients 117

The Cannigma

MAY 19, 2021

Japan does not have a medical cannabis program and does not allow the use of cannabis for patients seeking to treat a medical condition. In 2019, Japan approved clinical trials for Epidiolox — a cannabis derived medicine used to treat severe forms of childhood epilepsy such as Dravet and Lennox-Gastaut syndromes.

Law 137

Law Legalization Clinical Trials CBD 137

Cannabis Law Report

OCTOBER 2, 2021

MAPS PBC catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics. The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times.

Clinical Trials 52

Clinical Trials Research and Development Compliance Compliance 52

Cannabis Law Report

NOVEMBER 22, 2021

Andrew Forrest tips $5 million into medicinal cannabis company. Andrew Forrest is the latest billionaire to enter the medicinal cannabis arena with a $5 million share placement by his family’s investment arm Tattarang into Perth-based health technology company Emyria. The Sydney Morning Herald reports.

Clinical Trials 52

Clinical Trials Treatment Medicine Cannabinoids 52

Cannabis Law Report

SEPTEMBER 1, 2021

CYBN ) is a Toronto-based psychedelic medicine firm. The company recently became the industry’s first firm to list on the NYSE American exchange and their psilocybin clinical trial for depression is making excellent progress. At the moment, MindMed is hands-down the industry leader in LSD-inspired medicines.

Research and Development 102

Research and Development Therapy Clinical Trials Pharmaceutical 102

Puff Puff Post

OCTOBER 3, 2019

In a 47 acre greenhouse – close to the size of 42 football fields – GW is developing and delivering strains of medicinal cannabis. Leading the pilot research project is Dr. Eric Hollander, director of the Autism and Spectrum Program and Anxiety and Depression Program at Montefiore Hospital.

Research and Development 94

Research and Development Epilepsy Clinical Trials Treatment 94

SpeedWeed

MAY 22, 2021

The US Food and Drug Administration (FDA) has just approved a new clinical trial that will allow therapists to legally use MDMA. For this Phase 1 trial, MAPS will recruit 150 therapists that are currently being trained to conduct MDMA-assisted therapy sessions for PTSD. .

Clinical Trials 52

Clinical Trials Therapy Legalization Research and Development 52

Cannabis Law Report

JUNE 4, 2021

– Drug Demonstrates Efficacy and Safety in Advanced Prostate Cancer Patients. – Phase 2 Trial Underway. Scott Tagawa , a Professor of Medicine & Urology at Weill Cornell Medicine and an AIkido Pharma Scientific Advisory Board member. Declining circulating tumor cell (CTC) count in treated patients.

Data 100

Data Research and Development Clinical Trials Therapy 100

Cannabis Law Report

JANUARY 24, 2022

Accomplished leader to oversee Goldfinch Bio’s clinical function to advance precision medicines for people living with kidney disease. Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. CAMBRIDGE, Mass.–(BUSINESS

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

The Cannigma

AUGUST 26, 2021

Australia has a legal medical marijuana program, and while recreational cannabis remains illegal on the federal level, the enforcement of cannabis laws and the penalties handed out can differ widely from one territory to another. This also means that the TGA has not accessed these medicines for their safety, quality, or effectiveness.

Legalization 52

Legalization Access Medicine Clinical Trials 52

Cannabis Law Report

OCTOBER 13, 2021

Filed in support of the Company’s CYB004 pre-clinical development program, the PCT filing serves to increase the Company’s library of drug delivery modalities directed to optimal delivery of psychedelics and further strengthens Cybin’s growing IP portfolio. Vigorous scientific research and clinical trials are needed.

Clinical Trials 52

Clinical Trials Research and Development Treatment Conditions 52

Cannabis Law Report

JULY 25, 2022

Psychedelics, medicine and ethics has always been a tricky thing and we’re suprised (or maybe not) that those who have held themselves up to be the paragons of perfection in the field over the past few years, have in fact been either arrogant, dumb or lazy when it comes to managing ethics at their organisations.

Medicine 52

Medicine Therapy Research and Development Business 52

MedicalJane

JUNE 29, 2018

Food and Drug Administration (FDA) had approved only three cannabinoid-based medicines. The new drug is indicated for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. Prior to this week, the U.S.

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Puff Puff Post

JANUARY 13, 2020

Generally, states and regulators dissuade retailers from selling non-approved substances as medications, but a variety of people use CBD oil for a various medicinal purposes. So even when patients use CBD oil with essentially no THC, doctors need to understand a lot more about the complex chemical reactions of cannabinoids and terpenes.

CBD 52

CBD Clinical Trials Research and Development Oil 52

Puff Puff Post

JANUARY 13, 2020

Generally, states and regulators dissuade retailers from selling non-approved substances as medications, but a variety of people use CBD oil for a various medicinal purposes. So even when patients use CBD oil with essentially no THC, doctors need to understand a lot more about the complex chemical reactions of cannabinoids and terpenes.

CBD 52

CBD Clinical Trials Research and Development Oil 52

Cannabis Law Report

DECEMBER 6, 2021

–(BUSINESS WIRE)–Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced the appointment of Jeff W. Jacobs, Ph.D. as Chief Scientific Officer (CSO). Dr. Jacobs, who most recently served as CSO of Ardelyx, Inc.,

Research and Development 52

Research and Development Supply Chain Clinical Trials Medicine 52

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Commence clinical program in PTSD.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

JULY 9, 2021

In a typical scenario, psychedelic substances would be used in conjunction with psychotherapy sessions to treat disorders for which other medicinal therapies have failed. Beginning in 2018, the FDA has started to grant special designations to study the medicinal use of psilocybin via Breakthrough Therapy status. 360bbb-0a(a)(2).

Law 105

Law Therapy Clinical Trials Research and Development 105